FindTrial
Sign In

Safety and Efficacy of Immune Therapy for Condyloma

Safety and Efficacy of Immune Therapy for Condyloma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010855
Enrollment
Unknown
Registered
2017-03-14
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condyloma

Interventions

Intervention Group:DC-CIK+interferon-a
Control Group:saline+interferon-a

Sponsors

The Second People' s Hospital of Shenzhen City
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients have typical clinical characters of condyloma, positive for HPV-DNA test; All patients have been treated for cryotherapy or laser plus interferon for over half a year without completely recovery. All patients or their family will sign informed consent and approved by Ethics Committee of The Second People's Hospital of Shenzhen City

Exclusion criteria

Exclusion criteria: pregnant, blood disease, contraindication for immune therapy, allergic to interferon

Design outcomes

Primary

MeasureTime frame
Condyloma acuminatum recurrence rate;—

Secondary

MeasureTime frame
HPV gene;—

Countries

China

Contacts

Public ContactCuihong Lian

The Second People's Hospital of Shenzhen City

15814692161@163.com+86 15814692161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026